-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascletis Oral Obesity Drug Combination Shows 10.5% Weight Loss in Monkey Study

PUBT·11/16/2026 09:03:01
Listen to the news
Ascletis Oral Obesity Drug Combination Shows 10.5% Weight Loss in Monkey Study
  • Ascletis Pharma presented preclinical obesity treatment results at ObesityWeek 2026, held November 14-17 in Washington, DC.
  • Once-daily oral combination ASC30_48 FDC produced greater weight loss than ASC30 alone in monkeys, supporting further clinical development.
  • Injectable ASC37 reduced weight and food intake in obese mice; monkey studies supported potential monthly to quarterly dosing, pending clinical evaluation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261116-12413996), on November 16, 2026, and is solely responsible for the information contained therein.